Update Reimbursement Scheme Jardiance® 10mg - Chronic Kidney Disease

From February 1, 2024, the use of Jardiance^® (empagliflozin) in adult patients with chronic kidney disease, with and without diabetes type 2, is regularly reimbursed through the health insurance.

This means that the TBR for patients with chronic kidney disease will be stopped. The pharmacy or patient can declare medication dispensed in the period from July 24, 2023 to February 1, 2024 until  July 1, 2024 at the latest via TBR Nederland.

Conditions

Jardiance (empagliflozin) 10 mg was fully reimbursed through TBR Netherlands from July 24, 2023 to February 1, 2024. Medication dispensed during this period can be submitted until July 1, 2024 at the latest.

Who can submit a claim

Pharmacies, patients or their caregivers can claim the costs of Jardiance (empagliflozine) 10 mg for the treatment of chronic kidney disease online or by post. Online will be the fastest option.

More information on Jardiance® (empagliflozin) 10 mg webpage

^PC-NL-105354